Development of an automated chemiluminescent immunoassay for cancer antigen 72–4 and the evaluation of its analytical performance

Yanagihara, Fusamitsu; Okura, Hideaki; Ichikawa, Hisashi; Shirakawa, Takuma; Peng, You; Bailin, Tu; Zhang, Lin; Bonn, Ryan; Koduri, Sridevi; Schodin, Beth A.; Yoshimura, Toru

doi:10.1016/j.plabm.2023.e00308

Practical Laboratory Medicine

2023

DOI: 10.1016/j.plabm.2023.e00308

|View full text |Cite

Development of an automated chemiluminescent immunoassay for cancer antigen 72–4 and the evaluation of its analytical performance

Fusamitsu Yanagihara

Hideaki Okura

Hisashi Ichikawa

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

CA-125:CA72-4 ratio − towards a promising cost-effective tool in ovarian cancer diagnosis and monitoring of post-menopausal women under hormone treatment

Margoni,

Gargalionis,

Papavassiliou

2024

J Ovarian Res

View full text Add to dashboard Cite

Ovarian cancer (OC) is the most lethal gynecological cancer in the developed world. Most cases are diagnosed at late stage III-IV with a very low 5-year overall survival rate. Several studies revealed an elevated risk of OC in users of hormone treatment (HT) compared with non-users. The extended duration of HT is a statistically significant risk factor. Carbohydrate antigen or cancer antigen 125 (CA-125) remains the best screening tool for OC; however, its value is limited due to low specificity, leading to unnecessary interventions, surgeries, and psychological harm. Additionally, the variability of ultrasound interpretation highlights the urgent need to develop a univariate index with higher sensitivity and specificity for early diagnosis of OC in women under HT. Herein we critically review the limitations of biomarkers for the detection of OC aiming to suggest an accurate and cost-effective diagnostic ratio that eliminates the impact of body mass index, age, HT, smoking, and benign ovarian diseases on measurements. Numerous studies combine biomarkers such as CA-125, human epididymis protein 4, and thymidine kinase 1 into diagnostic algorithms. Data suggest that the expression of estrogen receptors may have diagnostic and prognostic value, as the estrogen receptor α (ERα):estrogen receptor β (ERβ) ratio is significantly higher in OC than in normal tissue due to ERβ downregulation. A high positive correlation between expression of CA-125 and carbohydrate antigen or cancer antigen 72 − 4 (CA72-4) with ERα and ERβ, respectively, poses that a novel ratio CA-125:CA72-4 could be nodal for monitoring post-menopausal women under HT.

show abstract

CA-125:CA72-4 ratio − towards a promising cost-effective tool in ovarian cancer diagnosis and monitoring of post-menopausal women under hormone treatment

Margoni,

Gargalionis,

Papavassiliou

2024

J Ovarian Res

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Development of an automated chemiluminescent immunoassay for cancer antigen 72–4 and the evaluation of its analytical performance

Cited by 1 publication

References 13 publications

CA-125:CA72-4 ratio − towards a promising cost-effective tool in ovarian cancer diagnosis and monitoring of post-menopausal women under hormone treatment

CA-125:CA72-4 ratio − towards a promising cost-effective tool in ovarian cancer diagnosis and monitoring of post-menopausal women under hormone treatment

Contact Info

Product

Resources

About